Pluses and minuses of the weight-loss drug bonanza cover art

Pluses and minuses of the weight-loss drug bonanza

Pluses and minuses of the weight-loss drug bonanza

Listen for free

View show details

About this listen

 Obesity treatments made by Novo Nordisk and Eli Lilly have spawned a healthcare revolution, with sales set to hit $150 bln by 2031. In this episode of The Big View, Peter Thal Larsen talks to Breakingviews Associate Editor Aimee Donnellan about their origins – and their impact. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.